ロード中...
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committee on Immunization Practices recommended vaccinatio...
保存先:
| 出版年: | Hum Vaccin Immunother |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6605828/ https://ncbi.nlm.nih.gov/pubmed/30625011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1558689 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|